Back to search results

Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer

This study is testing a new way to find if head and neck squamous cell carcinoma (HNSCC) has spread to the lymph nodes (small glands that are part of your immune system). We are looking at a drug called Indium In 111 Panitumumab, given through an IV, to see if it can help doctors find these cancer cells before surgery. You would also receive Panitumumab through an IV, and undergo SPECT/CT (a special imaging scan) and standard CT scans, followed by surgery. We are looking for people aged 19 and older with a confirmed diagnosis of HNSCC, including those with recurrent disease. The main goal is to see how safe Indium In 111 Panitumumab is, specifically looking for any side effects that are grade 2 or higher up to 15 days after the drug is given. This study aims to enroll 30 participants, but the current recruitment status is unclear.

Study design
This is an interventional study planning to enroll 30 participants. It is testing the safety and effectiveness of Indium In 111 Panitumumab.
What's involved
You would receive Indium In 111 Panitumumab and Panitumumab through an IV, undergo SPECT/CT and CT scans, and have standard surgical procedures.
Compensation
Not stated in the trial record.
Follow-up
Safety will be monitored for up to 15 days after the study drug is given.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05901545

Evaluating 111In Panitumumab for Nodal Staging in Head and Neck Cancer

Recruiting
PHASE1Ages 19+InterventionalTreatment
Vanderbilt-Ingram Cancer Center
~30 participants
Updated 2026-03-05 on ClinicalTrials.gov
What's tested:PanitumumabIndium In 111 PanitumumabSingle Photon Emission Computed TomographyComputed TomographySurgical ProcedureImaging agent

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of adverse events grade 2 or higher
Measured over Up to 15 days after administration of study drug

Conditions

Head and Neck Squamous Cell Carcinoma
Recurrent Head and Neck Squamous Cell Carcinoma

Explore related trials

Head and Neck Squamous Cell Carcinoma

Where it's being run

1 sites across 1 states
Tennessee1

Study leadership

  • Eben Rosenthal, MD · PRINCIPAL_INVESTIGATOR · Vanderbilt University/Ingram Cancer Center

Who to contact

Nicole Jones
[email protected]
615-936-2807
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 19 years.
Biopsy-confirmed diagnosis of squamous cell carcinoma of the head and neck, clinically-staged as node-negative (cN0) or as clinically-suspicious node(s).
Subjects diagnosed with any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection. Subjects with recurrent disease or a new primary will be allowed.
Planned standard of care elective neck dissection for node-negative or node-positive disease.
Have acceptable hematologic status, kidney function, and liver function including the following clinical results:
Hemoglobin ≥ 9 gm/dL
White blood cell count \> 3000/mm\^3
Platelet count ≥ 100,000/mm\^3
Serum creatinine ≤ 1.5 times upper reference range

Exclusion

Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment.
History of infusion reactions to monoclonal antibody therapies
History of allergies to iodine
Pregnant or breastfeeding.
Magnesium or potassium lower than the normal institutional values.
Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents.
Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis.
Severe renal disease or anuria.

What this trial measures

  • Incidence of adverse events grade 2 or higherUp to 15 days after administration of study drug

    Toxicity graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 5.0. Summarized by grade, severity and type